Rubicon Research acquires Cipla arm’s oral liquid, nasal product unit

July 09, 2021 10:52 pm | Updated July 13, 2021 03:36 pm IST - Mumbai

Rubicon Research Private Ltd., a specialty pharmaceutical company backed by General Atlantic, had acquired Cipla Ltd.’s wholly owned subsidiary Meditab Specialities Ltd.’s oral liquid dosage and nasal product manufacturing facility located in Satara, Maharashtra for an unspecified amount.

The facility is cGMP compliant and MHRA (U.K.) inspected production site that enables diverse pipeline of oral liquids for Rubicon Research. The company will seek additional regulatory approvals at the Satara site, including from the U.S. FDA.

“The acquisition of an outstanding oral liquid and nasal inhalers manufacturing facility advances our plan to offer a wider portfolio to our customers,” said Parag Sancheti, CEO, Rubicon Research in a statement. “These capabilities combined with our R&D expertise strengthens our ability to offer best-in-class drug products across dosage forms, which will benefit patients around the world.”

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.